INmune Bio Inc. has received research and development cash rebates totaling approximately $4.6 million from government programs in Australia and the United Kingdom. The company received about $4.2 million from Australia on July 30, 2026, and approximately $0.4 million from the UK during June 2026. After adjusting second-quarter operating cash flows to exclude the UK rebate, the combined proceeds exceeded the company's net cash used in operating activities during the quarter. CEO David Moss said the non-dilutive cash strengthens the balance sheet and extends the cash runway as INmune Bio advances its CORDStrom therapy toward regulatory filings.
INmune Bio IncReceives $4.6M in R&D cash rebates, strengthening balance sheet and extending cash runway.